Welcome to CSNpharm! For Research Use Only!
Home Compound Arrays Promotion +1-708-781-1677 sales@csnpharm.com    

CDK

CDK

Cat. No. Product Name CAS No. Information
CSN16440 Wogonin   632-85-9 Wogonin acts as an inhibitor of COX2 with IC50 of 46 M without affecting COX-1 and inhibits the NF-B pathway-mediated iNOs induction. Wogonin can be isolated from the root of scutellaria baicalensis georgi.
CSN24147 Voruciclib 1000023-04-0 Voruciclib is a protein kinase inhibitor specific for the cyclin-dependent kinase 4 (CDK4) with potential antineoplastic activity.
CSN25265 Trilaciclib 1374743-00-6 Trilaciclib is an inhibitor of CDK4 and CDK6 with IC50s of 1 nM and 4 nM, respectively.
CSN22094 Trilaciclib HCl 1977495-97-8 Trilaciclib hydrochloride is a CDK4/6 inhibitor with IC50s of 1 nM and 4 nM for CDK4 and CDK6, respectively.
CSN24801 TP353   1253799-29-9 TP353 is a CDK7 inhibitor.
CSN24290 THZ532 1702809-22-0 THZ532 is an inactive enantiomer of THZ531.
CSN16220 THZ1 1604810-83-4 THZ1 is a selective and potent covalent CDK7 inhibitor with IC50 binding affinity of 32 nM and inhibits Jurkat cells proliferation with IC50 of 50 nM
CSN22287 THAL-SNS-032 2139287-33-3 THAL-SNS-032 is a selective PROTAC, consisting of a CDK-binding SNS-032 ligand linked to a thalidomide derivative that binds the E3 ubiquitin ligase Cereblon (CRBN), targeting on CDK9.
CSN26130 TAK-931 1330782-76-7 TAK-931 is an oral CDC7-selective inhibitor as a candidate clinical anticancer drug. It induced S phase delay and replication stress.
CSN25349 SR-4853 2387704-62-1 SR-4835 is a potent, highly selective and ATP competitive dual inhibitor of CDK12/CDK13 with IC50 of 99 nM, Kd of 98 nM for CDK12 and Kd of 4.9 nM for CDK13. It acts in synergy with DNA-damaging chemotherapy and PARP inhibitors and provokes triple-negative breast cancer (TNBC) cell death.
CSN23869 Senexin B 1449228-40-3 Senexin B is a potent and selective CDK8/19 inhibitor.
CSN23674 SEL120-34A HCl 1609452-30-3 SEL120-34A HCl is a potent, selective, orally available, ATP-competitive CDK8 inhibitor, with IC50s of 4.4 nM and 10.4 nM for CDK8/CycC and CDK19/CycC, respectively, with antitumor activity.
CSN11862 Roscovitine   186692-46-6 Roscovitine is a potent and selective CDK inhibitor for Cdc2, CDK2 and CDK5 with IC50 of 0.65 μM, 0.7 μM and 0.16 μM and shows little effect on CDK4/6.
CSN19761 Roniciclib 1223498-69-8 Roniciclib is an orally bioavailable cyclin dependent kinase (CDK) inhibitor with potential antineoplastic activity, selectively binds to and inhibits the activity of CDK1/Cyclin B, CDK2/Cyclin E, CDK4/Cyclin D1, and CDK9/Cyclin T1, serine/threonine kinases that play key roles in the regulation of the cell cycle progression and cellular proliferation.
CSN22310 CDK9-PROTAC 2118356-96-8 PROTAC CDK9 Degrader-1 is a CRBN-recruiting PROTAC selectively targeting on CDK9, consist of a CDK9 ligand (aminopyrazole analog) linked to a CRBN E3 ligand thalidomide.
CSN25543 PNU 112455A 21886-12-4 PNU112455A HCl is an ATP site competetive inhibitor of CDK2 and CDK5. The Km for binding to the ATP site of CDK2 and CDK5 is 3.6 and 3.3 mM, respectively.
CSN16230 PHA-767491 845714-00-3 PHA-767491 is a potent ATP-competitive dual Cdc7Cdk9 inhibitor with IC50 values of 1034 nM and also an inhibitor of NRF2
CSN24146 PF-06873600 2185857-97-8 PF-06873600 is a selective and orally bioavailable inhibitor of cyclin-dependent kinase (CDK) with Ki of 0.09 nM, 0.13 nM and 0.16 nM for CDK2, CDK4 and CDK6 respectively. PF-06873600 has potential antineoplastic activity.
CSN18553 NVP-LCQ195 902156-99-4 NVP-LCQ195 is a small molecule heterocyclic inhibitor of CDK1, CDK2, CDK3 and CDK5 with IC50 of 1-42 nM.
CSN27187 NVP-2   1263373-43-8 NVP-2 is a potent and selective ATP-competitive CDK9 inhibitor with IC50 value of 0.5nM.
CSN25261 NSC-95397 93718-83-3 NSC 95397 is irreversible Cdc25 dual specificity phosphatase inhibitor with Ki values of 32, 96, and 40 nM for Cdc25A, Cdc25B, and Cdc25C, respectively.
CSN23650 ML 315 1440251-53-5 ML 315 is inhibitor of Clk and DYRK kinases with IC50s of 68, 68 and 231 nM for Clk1, Clk4 and Clk2, 282 and 1156 nM for Dyrk1A and Dyrk1B.
CSN23665 ML 315 HCl 2172559-91-8 ML 315 HCl is inhibitor of Clk and DYRK kinases with IC50s of 68, 68 and 231 nM for Clk1, Clk4 and Clk2, 282 and 1156 nM for Dyrk1A and Dyrk1B.
CSN24194 MC180295 2237942-08-2 MC180295 is a selective CDK9 inhibitor with IC50 values of 5nM, 112nM, 138nM, 159nM, 186nM, 233nM, 367nM, 399nM, 555nM and 712nM for CDK9-Cyclin T1, CDK4-Cyclin D, CDK1-Cyclin B, cdk5-p35, cdk5-p25, cdk2-cyclin A, cdk2-cyclin E, CDK3-Cyclin E, CDK7-CycH/MAT1 and cdk6-cyclin D3.
CSN26115 JSH-150 2247481-21-4 JSH-150 is a highly selective CDK9 kinase inhibitor with IC50 value of 1nM. It dose-dependently inhibited the phosphorylation of RNA Pol II, suppress the expression of MCL-1 and c-Myc, arrested the cell cycle and induced the apoptosis in the leukemia cells.
CSN22284 JH-XI-10-02 2209085-22-1 JH-XI-10-02 is a PROTAC selectively targeting on CDK8 with IC50 value of 159nM, and is consist of a warhead target on CDK8 (a Cortistatin A derivate) linked to CRBN ligand Pomalidomide.
CSN11014 Flavopiridol 146426-40-6 Flavopiridol is a pan CDK inhibitor with IC50 values of 30nM, 40nM, 20-40nM, 60nM, 875nM and 20nM for CDK1, 2, 4, 6, 7, 9, respectively
CSN11015 Flavopiridol HCl 131740-09-5 Flavopiridol HCl competes with ATP to inhibit CDKs including CDK1, CDK2, CDK4 and CDK6 with IC50 of ~ 40 nM.
CSN24779 EHT 5372 1425945-60-3 EHT 5372 is a strong inhibitor of DYRK’s family kinases, with IC50s of 0.22, 0.28 nM for DYRK1A and DYRK1B, respectively.
CSN18431 Dinaciclib   779353-01-4 Dinaciclib is a potent CDK inhibitor for CDK2, CDK5, CDK1 and CDK9 with IC50 of 1 nM, 1 nM, 3 nM and 4 nM, respectively.
CSN10712 Cucurbitacin E 18444-66-1 Cucurbitacin E is a widely available plant-derived natural product, making it a useful tool to study actin dynamics in cells and actin-based processes such as cytokinesis.
CSN22367 CDK8-IN-3 1884500-15-5 CDK8-IN-3 is an inhibitor of CDK8 extracted from patent WO2016041618A1, compound example 1.7.
CSN26129 CDK2 inhibitor 73 2079895-42-2 CDK2 inhibitor 73 is a selective CDK2 inhibitor with IC50 value of 44nM.
CSN23778 cc671 1618658-88-0 CC-671 is a selective inhibitor of TTK (Mps1) and CLK2 with IC50s of 5 nM and 3 nM, respectively.
CSN23969 BSJ-03-123 2361493-16-3 BSJ-03-123 is a PROTAC selectively targeting on CDK6, consist of a warhead palbociclib (a CDK inhibitor) linked to a CRBN ligand pomalidomide.
CSN25245 BS-194 1092443-55-4 BS-194 is a selective and potent CDK inhibitor with IC50 values of 3, 30, 30, 250, and 90nM for CDK2, CDK1, CDK5, CDK7, and CDK9, respectively.
CSN17259 Briciclib 865783-99-9 Briciclib is a small molecule that suppresses cyclin D1 accumulation in cancer cells
CSN20540 BRD6989 642008-81-9 BRD6989 selectively upregulates IL-10 through inhibiting CDK8 activity.
CSN24819 Bohemine 189232-42-6 Bohemine is a potent and selective, cell-permeable, cyclin-dependent kinase (CDK) inhibitor with IC50 = 1 µM. Bohemine is structurally similar to Olomoucine and Roscovitine.
CSN25300 BI-1347 2163056-91-3 BI-1347 is a potent CDK8 inhibitor with an IC50 of 1.1 nM.
CSN21503 AZD5438 602306-29-6 AZD5438 is a potent inhibitor of CDK129 with IC50 of 16620 nM
CSN24735 AZD4573 2057509-72-3 AZD4573 is a potent and selective CDK9 inhibitor with with nanomolar.
CSN21194 Atuveciclib Racemate 1414943-88-6 Atuveciclib Racemate is the racemate form of Atuveciclib.
CSN25869 Atuveciclib 1414943-94-4 Atuveciclib is an orally available and selective PTEFb/CDK9 inhibitor for the treatment of cancer.
CSN27194 (±)-BAY-1251152 1610358-53-6 (±)-BAY-1251152 is a racemic mixture form of BAY-1251152. BAY 1143572 is the first selective, orally available PTEFb/CDK9 inhibitor that entered clinical development with IC50 value of 3nM.
CSN26940 (-)-((2-((5-Fluoro-4-(4-fluoro-2-methoxyphenyl)pyridin-2-yl)amino)pyridin-4-yl)methyl)(imino)(methyl)-l6-sulfanone 1610358-59-2 (-)-BAY-1251152 is an enanthiomer of BAY-1251152 with rotation (-). BAY-1251152 is a potent and highly selective PTEF/CDK9 inhibitor.
<< PREV 1 2 3 4 NEXT >>